Welcome to our dedicated page for Dyne Therapeutics news (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Dyne Therapeutics, Inc. develops investigational therapies for genetically driven neuromuscular diseases using its FORCE platform, which is designed to deliver payloads to muscle tissue and the central nervous system. Company news centers on clinical programs in Duchenne muscular dystrophy and myotonic dystrophy type 1, including z-rostudirsen, z-basivarsen, the DELIVER, ACHIEVE and HARMONIA studies, and preclinical work in additional neuromuscular diseases.
Recurring updates include clinical data presentations, FDA interactions and designations, financial results, cash-resource commentary, medical-conference abstracts, access-related research, investor conference participation and Nasdaq inducement equity grants.
Dyne Therapeutics (Nasdaq: DYN) said management will participate in several investor conferences in March 2026, including TD Cowen (fireside chat Mar 4), Jefferies Biotech on the Beach (meetings Mar 10–11) and Stifel Virtual CNS Forum (fireside chat Mar 17).
Live webcasts of each fireside chat will be available on Dyne's Investors & Media site and replays accessible for 90 days.
Dyne Therapeutics (Nasdaq: DYN) will present five abstracts, including three oral talks, at the 2026 MDA Clinical & Scientific Conference March 8-11, 2026, covering Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and Pompe disease.
Highlights include late-breaking DELIVER cardiopulmonary function data for z-rostudirsen (DYNE-251), a Phase 3 design for z-basivarsen (DYNE-101) in DM1, and preclinical DYNE-401 Pompe data; posters and slides will be posted on the company website in sync with the conference.
Dyne Therapeutics (Nasdaq: DYN) announced that Japan's Ministry of Health, Labour and Welfare granted Orphan Drug designation to zeleciment basivarsen (z-basivarsen) for the treatment of myotonic dystrophy type 1 (DM1) on January 20, 2026. Z-basivarsen is in a Phase 1/2 ACHIEVE trial and has shown sustained functional improvement in myotonia, muscle strength and function with a favorable safety profile. Dyne expects to complete enrollment in the ACHIEVE Registrational Expansion Cohort in early Q2 2026. The designation in Japan complements prior U.S. and European designations and may provide development subsidies and up to 10 years of market exclusivity if approved.
Dyne Therapeutics (Nasdaq: DYN) announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET).
A live webcast will be available in the Investors & Media section of Dyne’s website and a replay will be accessible for 30 days.
Dyne Therapeutics (Nasdaq: DYN) appointed Vikram Karnani to its Board of Directors on December 23, 2025. Mr. Karnani is CEO of Collegium Pharmaceutical since November 2024 and previously led commercial and rare disease operations at Amgen and Horizon Therapeutics.
The company said his commercial and launch experience will support Dyne’s advance toward commercialization and a potential first launch in Q1 2027. Background details include leadership roles tied to a $28 billion acquisition integration and helping grow a Horizon rare disease business from $500M to over $3B in revenue.
Dyne Therapeutics (Nasdaq: DYN) closed an upsized underwritten public offering on Dec 11, 2025, selling 21,827,549 shares of common stock at a public offering price of $18.44 per share.
The total gross proceeds to Dyne were approximately $402.5 million before underwriting discounts, commissions and offering expenses. The offering included 2,847,071 shares issued upon full exercise of the underwriters' option to purchase additional shares. All shares were sold by Dyne under a shelf registration on Form S-3 that became effective March 5, 2024.
Dyne Therapeutics (Nasdaq: DYN) priced an upsized underwritten public offering of 18,980,478 common shares at $18.44 per share, expected to raise $350.0 million in gross proceeds before fees. The offering is expected to close on or about December 11, 2025, subject to customary closing conditions.
Dyne sold all shares in the offering and granted underwriters a 30-day option to purchase up to an additional 2,847,071 shares at the public offering price, less underwriting discounts and commissions.
Dyne Therapeutics (Nasdaq: DYN) announced on Dec 8, 2025 that it commenced an underwritten public offering of $300,000,000 of common stock with a 30-day option for underwriters to purchase up to an additional $45,000,000 of shares.
All shares in the proposed offering are to be sold by Dyne. The offering is subject to market and other conditions and will be made pursuant to a Form S-3 shelf registration filed on March 5, 2024. Morgan Stanley, Jefferies, Stifel and Guggenheim Securities are joint book-running managers. A preliminary prospectus supplement is expected to be filed with the SEC and final terms will appear in a final prospectus supplement.
Dyne Therapeutics (Nasdaq: DYN) announced positive topline results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of z-rostudirsen (DYNE-251) in Duchenne muscular dystrophy amenable to exon 51 skipping. The REC met its primary endpoint with muscle-content adjusted dystrophin rising to 5.46% of normal at 6 months (p<0.0001), replicating a seven-fold increase from prior MAD data.
Functional improvement was observed across six prespecified endpoints with nominal significance for TTR and 10MWR velocity, lung function (FVC%p) was preserved at 6 months, safety remained favorable across 86 participants, and Dyne plans a U.S. Accelerated Approval BLA filing in Q2 2026.
Dyne Therapeutics (Nasdaq: DYN) will announce topline results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of zeleciment rostudirsen (z-rostudirsen, DYNE-251) on December 8, 2025.
The company will host an investor conference call and webcast at 8:00 a.m. ET on that day; a press release will be issued before the event. The webcast and an accompanying slide presentation will be available on Dyne’s Events & Presentations page, and a replay will be accessible for 90 days after the presentation.